Enterprise Value
10.71B
Cash
1.861B
Avg Qtr Burn
-122.2M
Short % of Float
5.17%
Insider Ownership
4.25%
Institutional Own.
88.09%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 4 Data readout | ||
ELEVIDYS (SRP-9001) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
AMONDYS 45 (casimersen) (SRP-4045) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
EXONDYS 51 (eteplirsen) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
VYONDYS 53 (golodirsen) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
ELEVIDYS (SRP-9001) Details Duchenne muscular dystrophy | Phase 3 Update | |
SRP-5051 Details Duchenne muscular dystrophy | Phase 2 Data readout | |
SRP-6004 Details Limb-Girdle Muscular Dystrophy, Dysferlinopathy | Phase 1 Data readout | |
SRP-9003 (bidridistrogene xeboparvovec) Details Limb-Girdle Muscular Dystrophy | Phase 1 Update |